{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-PI9NODD4/f6cc3a0c-8205-4a94-9dad-f530eae476af/PDF","dcterms:extent":"121 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-PI9NODD4/fbf71ec7-6526-4639-91bc-0c351707562a/TEXT","dcterms:extent":"10 KB"}],"edm:TimeSpan":{"@rdf:about":"1994-2025","edm:begin":{"@xml:lang":"en","#text":"1994"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-PI9NODD4","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-46R7GGHL"},{"@xml:lang":"sl","#text":"Medicinski razgledi"}],"dcterms:issued":"2011","dc:creator":["Barbič-Žagar, Breda","Bevec, Matevž","Bon, Jurij"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:50"},{"@xml:lang":"sl","#text":"str. 97-99"}],"dc:identifier":["ISSN:0025-8121","COBISSID:2976113","URN:URN:NBN:SI:doc-PI9NODD4"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Medicinski razgledi"},"dc:subject":[{"@xml:lang":"sl","#text":"bipolarna manija"},{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"olanzapin"},{"@xml:lang":"sl","#text":"shizofrenija"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"zdravila"},{"@xml:lang":"sl","#text":"zdravljenje"},{"@rdf:resource":"http://www.wikidata.org/entity/Q41112"}],"dcterms:temporal":{"@rdf:resource":"1994-2025"},"dc:title":{"@xml:lang":"sl","#text":"Neintervencijsko spremljanje učinkovitosti in varnosti olanzapina (Zolrix) v zdravljenju shizofrenije in bipolarne manije| Post-authorization safety and efficacy study of olanzapine (Zolrix) in the treatment of shizophrenia and bipolar mania|"},"dc:description":[{"@xml:lang":"sl","#text":"Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseeses. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enablcs effeceive treatment at reduced strength and frequency of adverse reactions. We conducted a post authorisation study in which 163 patients with schizophrenia and bipolar maniareceived olanzapine in the form of regular and orodispersible tablets (Zolrix / Zolrix orodispersible tablets, Krka, d. d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduccd symptom expression in 79% of patients. Dueto improvement in symptoms 41%, of patients became only marginally ill or even symptom-free Olanzapine was very well tolerated by patients. Only in 25% of patients medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number feel to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapine"},{"@xml:lang":"sl","#text":"Shizofrenija in bipolarna motnja sta duševni motnji, ki v svetu predstavljata pomemben javnozdravstveni problem, ki ga je z dovolj zgodnjim odkrivanjem in zdravljenjem mogoče razmeroma dobro obvladovati in nadzorovati. V želji izboljšati učinkovitost in varnost zdravljenja z antipsihotiki se z razvojem antipsihotikov druge generacije povečuje možnost za izbiro ustreznega oz. optimalnega zdravila ter tako omogoča učinkovito zdravljenje ob zmanjšani jakosti in pogostnosti neželenih učinkov. Izvedli smo neintervencijsko preizkušanje, v katerem je 163 bolnikov s shizofrenijo in bipolarno manijo jemalo olanzapin v obliki navadnih in orodisperzibilnih tablet (Zolrixr/Zolrixr orodisperzibilne tablete, Krka, d.d., Novo mesto). Zdravljenje s povprečnim odmerkom olanzapina 12,7 mg je zmanjšalo izraženost simptomov pri 79 % bolnikov, 41 % bolnikov je bilo zaradi izboljšanja simptomov le še mejno bolnih ali celo brez znakov bolezni. Bolniki so olanzapin zelo dobro prenašali. Le 25,2 % bolnikov je imelo med spremljanjem neželene učinke, ki so jih povezovali z zdravilom, ob koncu spremljanja pa le še 17,8 %. Neintervencijsko preizkušanje je pokazalo, da je najpogostejši neželeni učinek povečanje telesne teže, prisoten le pri 11 % bolnikov, zdravljenih z olanzapinom"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-PI9NODD4","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-PI9NODD4"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-PI9NODD4/f6cc3a0c-8205-4a94-9dad-f530eae476af/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo Medicinski razgledi"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-PI9NODD4/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-PI9NODD4"}}}}